Simcere Pharmaceutical Group Limited
2096
Classificação em ações
#4480
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the... Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Preço da ação
$1.32
Valor de mercado
$3.40B
Variação (1 dia)
-4.51%
Variação (1 ano)
-19.88%
País
CN
Negociar Simcere Pharmaceutical Group Limited (2096)
Categoria
Healthcare
Margem Operacional de Simcere Pharmaceutical Group Limited (2096)
Margem Operacional em October 2026 TTM: 20.94%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Simcere Pharmaceutical Group Limited, a margem operacional atual (TTM) é 20.94%. No final de 2024, a margem operacional era 12.78%.
Histórico da Margem Operacional da Simcere Pharmaceutical Group Limited de 2012 a 2026
Margem Operacional no final de cada ano
| Ano | Margem Operacional | Alterar |
|---|---|---|
| 2026 (TTM) | 20.94% | 4.08% |
| 2025 | 20.12% | 57.43% |
| 2024 | 12.78% | 18.66% |
| 2023 | 10.77% | -21.10% |
| 2022 | 13.65% | -52.88% |
| 2021 | 28.97% | 40.90% |
| 2020 | 20.56% | -11.61% |
| 2019 | 23.26% | 11.45% |
| 2018 | 20.87% | 52.11% |
| 2017 | 13.72% | 196.33% |
| 2012 | 4.63% | 0.00% |
Margem Operacional de empresas semelhantes ou concorrentes
| Empresa | Margem Operacional | Diferença na Margem Operacional | País |
|---|---|---|---|
| 38.59% | -98.16% |
US
|
|
| -149.01% | -107.12% |
US
|
|
| 25.57% | -98.78% |
AU
|
|
| 28.81% | -98.62% |
NL
|
|
| 31.23% | -98.51% |
BE
|
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.